Study: L-Ergothioneine Capsules & Liver Function
Qingdao Central Hospital | 2024–2025

This single-center, open-label clinical trial enrolled 30 adults (ages 18–65) with abnormal liver enzyme levels. Participants took 60mg of L-ergothioneine daily (two 30mg capsules) for 30 consecutive days.

Key Findings (n=30, all completers):

• AST dropped by 12.7% at 15 days and 19.6% at 30 days (p = 0.0082)
• ALT dropped by 15.6% at 15 days and 21.3% at 30 days (p = 0.0025)
• GGT dropped by 11.5% at 15 days (p = 0.0270)
• Physical function (fatigue, dizziness, liver discomfort, dry eyes, etc.) improved by 39% after 30 days (p < 0.0001)
• Daytime dysfunction (drowsiness, energy levels) improved by 51.6% after 30 days (p = 0.0038)
• No adverse events were reported, with no negative impact on liver synthesis function or blood lipid levels

Conclusion: Just 30 days of L-ergothioneine supplementation was associated with significant reductions in key liver enzyme markers and meaningful improvements in physical wellbeing and daytime energy, with a clean safety profile.

Study: Ergothioneine Capsules & Ovarian Reserve Function
Qingdao Central Hospital | 2025–2026

This single-center, open-label clinical trial (ChiCTR2500104484) enrolled 40 women aged 35–45 with low ovarian reserve (AMH < 3.0 ng/mL). Participants took 60mg of ergothioneine daily (two 30mg capsules twice daily) over three consecutive menstrual cycles.

Key Findings (n=36 completers):

• AMH levels rose from 1.79 to 2.47 ng/mL (p = 0.0292)
• FSH levels decreased from 8.22 to 7.05 mIU/mL (p = 0.0317)
• Estradiol (E₂) increased from 46.00 to 63.46 ng/mL (p = 0.0305)
• Menopausal symptoms (Kupperman score) improved significantly, with effects strengthening over time (p < 0.0001)
• Sleep quality (PSQI) and menstrual status both showed statistically significant improvements
• No adverse reactions were reported throughout the study period

Conclusion: Three months of ergothioneine supplementation was associated with meaningful improvements in hormonal markers of ovarian reserve, menopausal symptoms, sleep, and menstrual regularity, with a favorable safety profile.

Study: Ergothioneine Capsules & Postpartum Health
Huainan First People's Hospital | 2025–2026

This randomized, double-blind, placebo-controlled clinical trial enrolled 40 postpartum women (ages 22–40, within 0–24 months postpartum) with impaired quality of life scores. Participants took 120mg of ergothioneine daily (two 30mg capsules twice daily) for 30 consecutive days, compared against a placebo group.

Key Findings (n=40, all completers):

• Quality of life (SF-36 total score) improved by 35.94% vs. baseline (p = 0.0006), outperforming the placebo group across multiple dimensions including vitality, mental health, and physical role function
• Physical fatigue improved by 27.78% (p = 0.0042), significantly better than the placebo group
• Sleep quality (PSQI total score) improved by 29.24% (p = 0.0001), with improvements across sleep onset, duration, efficiency, and daytime function
• Qi and blood deficiency (TCM syndrome scale) improved by 42.78% (p = 0.0012), outperforming placebo
• Liver enzymes ALT and AST both improved significantly (30.42% and 17.44% respectively), while the placebo group showed no change
• No adverse events were reported throughout the study period

Conclusion: Thirty days of ergothioneine supplementation led to meaningful, placebo-beating improvements in postpartum quality of life, fatigue, sleep, emotional wellbeing, and liver health, with an excellent safety profile.

Study: Ergothioneine Capsules & Dysmenorrhea (Period Pain)
Qingdao Central Hospital | 2025–2026

This randomized, double-blind, placebo-controlled clinical trial enrolled 40 women (ages 18–35) with primary dysmenorrhea and a baseline pain VAS score of 4 or above. Participants took 120mg of ergothioneine daily (two 30mg capsules twice daily) over three consecutive menstrual cycles, compared against a placebo group.

Key Findings (n=20 per group, all completers):

• Peak pain (VAS score) dropped from 4.8 to 2.3 points over three cycles in the ergothioneine group (p < 0.001), while the placebo group showed no significant change — confirming the effect was beyond natural recovery or placebo
• Dysmenorrhea symptom score fell from 9.6 to 5.7 points (p < 0.05), significantly better than placebo by the third cycle (p = 0.0282)
• CMSS score (measuring overall menstrual symptom severity including pain, physical discomfort, and mood) dropped from 29.2 to 16.4 points (p < 0.05), with no meaningful change in the placebo group
• All three pain and symptom measures showed greater improvement with each successive cycle, suggesting a cumulative benefit
• No adverse reactions were reported throughout the study period

Conclusion: Three months of ergothioneine supplementation produced progressive, placebo-beating reductions in period pain intensity and associated symptoms, with a strong safety profile. The study authors note that larger, longer trials are needed to further validate these findings.Add your content here.